Kunjin virus replicon vectors for human immunodeficiency virus vaccine development

被引:41
作者
Harvey, TJ
Anraku, I
Linedale, R
Harrich, D
Mackenzie, J
Suhrbier, A
Khromykh, AA [1 ]
机构
[1] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Brisbane, Qld 4029, Australia
[2] Univ Queensland, Clin Med Virol Ctr, Brisbane, Qld, Australia
[3] Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Queensland Inst Med Res, Brisbane, Qld, Australia
关键词
D O I
10.1128/JVI.77.14.7796-7803.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have previously demonstrated the ability of the vaccine vectors based on replicon RNA of the Australian flavivirus Kunjin (KUN) to induce protective antiviral and anticancer CD8(+) T-cell responses using murine polyepitope as a model immunogen (I. Anraku, T. J. Harvey, R. Linedale, J. Gardner, D. Harrich, A. Suhrbier, and A. A. Khromykh, J. Virol. 76:3791-3799, 2002). Here we showed that immunization of BALB/c mice with KUN replicons encoding HIV-1 Gag antigen resulted in induction of both Gag-specific antibody and protective Gag-specific CD8(+) T-cell responses. Two immunizations with KUNgag replicons in the form of virus-like particles (VLPs) induced anti-Gag antibodies with titers of greater than or equal to1:10,000. Immunization with KUNgag replicons delivered as plasmid DNA, naked RNA, or VLPs induced potent Gag-specific CD8(+) T-cell responses, with one immunization of KUNgag VLPs inducing 4.5-fold-more CD8(+) T cells than the number induced after immunization with recombinant vaccinia virus carrying the gag gene (rVVgag). Two immunizations with KUNgag VLPs also provided significant protection against challenge with rVVgag. Importantly, KUN replicon VLP vaccinations induced long-lasting immune responses with CD8(+) T cells able to secrete gamma interferon and to mediate protection 6 to 10 months after immunization. These results illustrate the potential value of the KUN replicon vectors for human immunodeficiency virus vaccine design.
引用
收藏
页码:7796 / 7803
页数:8
相关论文
共 44 条
[1]   GLYCOSYLATION AND ANTIGENIC VARIATION AMONG KUNJIN VIRUS ISOLATES [J].
ADAMS, SC ;
BROOM, AK ;
SAMMELS, LM ;
HARTNETT, AC ;
HOWARD, MJ ;
COELEN, RJ ;
MACKENZIE, JS ;
HALL, RA .
VIROLOGY, 1995, 206 (01) :49-56
[2]   Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV [J].
Altes, HK ;
Price, DA ;
Jansen, VAA .
VACCINE, 2001, 20 (1-2) :3-6
[3]   Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity [J].
Anraku, I ;
Harvey, TJ ;
Linedale, R ;
Gardner, J ;
Harrich, D ;
Suhrbier, A ;
Khromykh, AA .
JOURNAL OF VIROLOGY, 2002, 76 (08) :3791-3799
[4]   Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity [J].
Belyakov, IM ;
Moss, B ;
Strober, W ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4512-4517
[5]   Efficiency of a myogenic DNA vaccine is strictly dependent upon cellular localization of HIV-1Pr55gag [J].
Bojak, A ;
Wild, J ;
Wolf, H ;
Wagner, R .
VACCINE, 2002, 20 (15) :1980-1984
[6]  
Coffin JM, 1997, RETROVIRUSES
[7]   Alphavirus replicon particles as candidate HIV vaccines [J].
Davis, NL ;
West, A ;
Reap, E ;
MacDonald, G ;
Collier, M ;
Dryga, S ;
Maughan, M ;
Connell, M ;
Walker, C ;
McGrath, K ;
Cecil, C ;
Ping, LH ;
Frelinger, J ;
Olmsted, R ;
Keith, P ;
Swanstrom, R ;
Williamson, C ;
Johnson, P ;
Montefiori, D ;
Johnston, RE .
IUBMB LIFE, 2002, 53 (4-5) :209-211
[8]   Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients [J].
Durali, D ;
Morvan, J ;
Letourneur, F ;
Schmitt, D ;
Guegan, N ;
Dalod, M ;
Saragosti, S ;
Sicard, D ;
Levy, JP ;
Gomard, E .
JOURNAL OF VIROLOGY, 1998, 72 (05) :3547-3553
[9]   Vaccine development against HIV-1 - Current perspectives and future directions [J].
Edgeworth, RL ;
Juan, HS ;
Rosenzweig, JA ;
Nguyen, NL ;
Boyer, JD ;
Ugen, KE .
IMMUNOLOGIC RESEARCH, 2002, 25 (01) :53-74
[10]   Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection [J].
Gandhi, RT ;
Walker, BD .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (04) :487-494